| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1616481 | Inhibition of N-terminal 6x-His-tagged recombinant human cIAP1-BIR3 (258 to 363 residues) expressed in Escherichia coli incubated for 2 hrs without 6 hrs pre-incubation with enzyme by biotinylated AVPI peptide based DELFIA | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695638 | Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed inhibition of tumor growth at 100 mg/kg, po administered daily for 5 days/week for 2 weeks | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695651 | Tmax in human MDA-MB-231 cells xenografted SCID mouse plasma at 30 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695456 | Competitive inhibition of human cIAP1 BIR3 domain expressed in Escherichia coli BL21(DE3) after 2 to 3 hrs by fluorescence polarization assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616496 | Cytotoxicity in human SK-MEL-28 cells assessed as reduction in cell viability in presence of 1 ng/mL TNFlpha measured every 3 hrs for 4 days by IncuCyteS3 live-cell analysis system based assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID1239121 | Antitumor activity against human MDA-MB-231 cells xenografted in Balb/c SCID mouse assessed as tumor growth inhibition at 100 mg/kg, po qd measured every 3 days | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. |
| AID695668 | AUC (0 to t) in human MDA-MB-231 cells xenografted SCID mouse tumor at 100 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695659 | AUC (0 to t) in human MDA-MB-231 cells xenografted SCID mouse tumor at 10 mg/kg, iv administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616489 | Induction of cIAP1 degradation in human A549 cells assessed as reduction in cIAP1 protein level at 1 uM incubated for 3 hrs by Western blot analysis | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695655 | Cmax in human MDA-MB-231 cells xenografted SCID mouse plasma at 100 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695635 | Toxicity in human MDA-MB-231 cells xenografted in SCID mouse at 100 mg/kg, po administered daily for 5 days/week for 2 to 3 weeks | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695670 | Tmax in human MDA-MB-231 cells xenografted SCID mouse tumor at 100 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616497 | Cytotoxicity in human A549 cells assessed as reduction in cell viability in presence of 1 ng/mL TNFlpha measured every 3 hrs for 4 days by IncuCyteS3 live-cell analysis system based assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695677 | Inhibition of human ERG at 30 uM | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695653 | Oral bioavailability in human MDA-MB-231 cells xenografted SCID mouse plasma at 30 mg/kg administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695455 | Competitive inhibition of human XIAP BIR3 domain expressed in Escherichia coli BL21(DE3) after 2 to 3 hrs by fluorescence polarization assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695676 | Inhibition of Cytochrome P450 | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1659181 | Binding affinity to N-terminal His-tagged Zika virus NS2B-NS3 protease (1 to 187 residues) using Boc-Gly-Arg-Arg-AMC as substrate | 2020 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
| Inhibitors of the Zika virus protease NS2B-NS3. |
| AID1616494 | Induction of apoptosis in human SK-MEL-28 cells assessed as increase in caspase-3/7 activity at 2.5 uM incubated for 36 hrs in presence of 1 ng/mL TNFlpha by IncuCyteS3 caspase-3/7 fluorescence-based apoptosis assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695646 | Tmax in human MDA-MB-231 cells xenografted SCID mouse plasma at 10 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695675 | Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed inhibition of tumor growth at 100 mg/kg, po administered daily for 5 days/week for 2 weeks measured on day 36 relative to untreated control | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616490 | Induction of cIAP2 degradation in human SK-MEL-28 cells assessed as reduction in cIAP2 protein level at 1 uM incubated for 3 hrs by Western blot analysis | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695663 | Cmax in human MDA-MB-231 cells xenografted SCID mouse tumor at 10 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695661 | Tmax in human MDA-MB-231 cells xenografted SCID mouse tumor at 10 mg/kg, iv administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1239110 | Cytotoxicity against human insensitive HCT116 cells assessed as inhibition of cell growth after 72 hrs by Alamar Blue assay | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. |
| AID1659171 | Inhibition of N-terminal His-tagged Zika virus NS2B-NS3 protease (1 to 187 residues) using Boc-Gly-Arg-Arg-AMC as substrate | 2020 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
| Inhibitors of the Zika virus protease NS2B-NS3. |
| AID1616480 | Binding affinity to N-terminal His-tagged human XIAP-BIR3 (253 to 347 residues) expressed in Escherichia coli BL21-Gold(DE3) pLysS assessed as change in melting temperature incubated for for 6 hrs at 37 degC by SYPRO orange dye based thermal shift assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695644 | AUC (0 to t) in human MDA-MB-231 cells xenografted SCID mouse plasma at 10 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616495 | Induction of apoptosis in human A549 cells assessed as increase in caspase-3/7 activity at 2.5 uM incubated for 36 hrs in presence of 1 ng/mL TNFlpha by IncuCyteS3 caspase-3/7 fluorescence-based apoptosis assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695642 | Cmax in human MDA-MB-231 cells xenografted SCID mouse plasma at 10 mg/kg, iv administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616492 | Induction of apoptosis in human SK-MEL-28 cells assessed as increase in caspase-3/7 activity at 2.5 uM incubated for 36 hrs by IncuCyteS3 caspase-3/7 fluorescence-based apoptosis assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695672 | Induction of cell death in human MDA-MB-231 cells incubated for 24 hrs by trypan blue exclusion assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695664 | Tmax in human MDA-MB-231 cells xenografted SCID mouse tumor at 10 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695470 | Induction of apoptosis in human MDA-MB-231 cells assessed as activation of caspase-3 activity at 1.5 uM after 12 hrs by Western blot analysis | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695647 | Half life in human MDA-MB-231 cells xenografted SCID mouse plasma at 10 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1239107 | Antagonist activity at cIAP1-BIR3 domain (unknown origin) assessed as inhibition of interaction with SMAC at 0.01 uM by fluorescence polarization assay relative to control | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. |
| AID695669 | Cmax in human MDA-MB-231 cells xenografted SCID mouse tumor at 100 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695662 | AUC (0 to t) in human MDA-MB-231 cells xenografted SCID mouse tumor at 10 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616488 | Induction of cIAP1 degradation in human SK-MEL-28 cells assessed as reduction in cIAP1 protein level at 1 uM incubated for 3 hrs by Western blot analysis | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695658 | Oral bioavailability in human MDA-MB-231 cells xenografted SCID mouse plasma at 100 mg/kg administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695472 | Toxicity in human MCF12F cells assessed as induction of cell death at 10 uM after 48 hrs by trypan blue exclusion assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616479 | Binding affinity to N-terminal His-tagged human XIAP-BIR3 (253 to 347 residues) expressed in Escherichia coli BL21-Gold(DE3) pLysS assessed as change in melting temperature incubated for for 2 hrs at room temperature by SYPRO orange dye based thermal shif | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695657 | Half life in human MDA-MB-231 cells xenografted SCID mouse plasma at 100 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695648 | Oral bioavailability in human MDA-MB-231 cells xenografted SCID mouse plasma at 10 mg/kg administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695468 | Growth inhibition of human SKOV3 cells after 4 days by WST8 assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695457 | Competitive inhibition of human cIAP2 BIR3 domain expressed in Escherichia coli BL21(DE3) after 2 to 3 hrs by fluorescence polarization assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1239108 | Cytotoxicity against human sensitive EVSA-T cells assessed as inhibition of cell growth after 72 hrs by Alamar Blue assay | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. |
| AID1616476 | Inhibition of N-terminal 6x-His-tagged recombinant human cIAP2-BIR3 (244 to 349 residues) expressed in Escherichia coli incubated for 2 hrs without 6 hrs pre-incubation with enzyme by biotinylated AVPI peptide based DELFIA | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695641 | AUC (0 to t) in human MDA-MB-231 cells xenografted SCID mouse plasma at 10 mg/kg, iv administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695643 | Half life in human MDA-MB-231 cells xenografted SCID mouse plasma at 10 mg/kg, iv administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695654 | AUC (0 to t) in human MDA-MB-231 cells xenografted SCID mouse plasma at 100 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1239105 | Antagonist activity at XIAP-BIR3 domain (unknown origin) assessed as inhibition of interaction with SMAC at 0.05 uM by fluorescence polarization assay relative to control | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. |
| AID1616477 | Inhibition of N-terminal His-tagged human XIAP-BIR3 (253 to 347 residues) expressed in Escherichia coli BL21-Gold(DE3) pLysS incubated for 2 hrs without 6 hrs pre-incubation with enzyme by biotinylated AVPI peptide based DELFIA | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695678 | Toxicity in dog assessed as drug tolerability | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1239111 | Antagonist activity at full-length FLAG-tagged XIAP (unknown origin) transfected in HEK293 cells assessed as inhibition of interaction with caspase 9 after 2 hrs by immunoprecipitation assay | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. |
| AID695469 | Induction of cell death in human MDA-MB-231 cells at 1 uM by trypan blue exclusion assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695471 | Induction of apoptosis in human MDA-MB-231 cells assessed as activation of PARP cleavage at 1.5 uM after 12 hrs by Western blot analysis | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616487 | Covalent binding affinity to HA-BIR3 domain of XIAP (unknown origin) expressed in HEK293T cells assessed as increase in band intensity at 10 uM incubated for 6 hrs by Western blot analysis | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID1616478 | Inhibition of N-terminal His-tagged human XIAP-BIR3 (253 to 347 residues) expressed in Escherichia coli BL21-Gold(DE3) pLysS incubated for 2 hrs after 6 hrs pre-incubation with enzyme by biotinylated AVPI peptide based DELFIA | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695460 | Antagonist activity at human XIAP BIR3 domain assessed as restoration of caspase 9 activity using human MDA-MB-231 cells lysates using Z-LEHD-AFC by fluorescence assay based cell-free assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695649 | AUC (0 to t) in human MDA-MB-231 cells xenografted SCID mouse plasma at 30 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616493 | Induction of apoptosis in human A549 cells assessed as increase in caspase-3/7 activity at 2.5 uM incubated for 36 hrs by IncuCyteS3 caspase-3/7 fluorescence-based apoptosis assay | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID1616483 | Inhibition of N-terminal 6x-His-tagged recombinant human cIAP2-BIR3 (244 to 349 residues) expressed in Escherichia coli incubated for 2 hrs after 6 hrs pre-incubation with enzyme by biotinylated AVPI peptide based DELFIA | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695660 | Cmax in human MDA-MB-231 cells xenografted SCID mouse tumor at 10 mg/kg, iv administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695652 | Half life in human MDA-MB-231 cells xenografted SCID mouse plasma at 30 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616491 | Induction of cIAP2 degradation in human A549 cells assessed as reduction in cIAP2 protein level at 1 uM incubated for 3 hrs by Western blot analysis | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695666 | Cmax in human MDA-MB-231 cells xenografted SCID mouse tumor at 30 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695673 | Induction of cell death in human MDA-MB-231 cells at 1 uM incubated for 24 hrs by trypan blue exclusion assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616486 | Stability in mouse plasma assessed as half life at 200 uM at 37 degC incubated up to 120 mins by mass spectrometry | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695679 | Aqueous solubility of the compound | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695674 | Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed inhibition of tumor growth at 100 mg/kg, po administered daily for 5 days/week for 2 weeks measured on day 50 relative to untreated control | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1616482 | Inhibition of N-terminal 6x-His-tagged recombinant human cIAP1-BIR3 (258 to 363 residues) expressed in Escherichia coli incubated for 2 hrs after 6 hrs pre-incubation with enzyme by biotinylated AVPI peptide based DELFIA | 2019 | Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
| Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy. |
| AID695473 | Toxicity in in human prostate epithelial cells assessed as induction of cell death at 10 uM after 48 hrs by trypan blue exclusion assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695462 | Induction of degradation of cIAP1 in human MDA-MB-231 cells at 100 nM after 15 mins by Western blot analysis | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695656 | Tmax in human MDA-MB-231 cells xenografted SCID mouse plasma at 100 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695650 | Cmax in human MDA-MB-231 cells xenografted SCID mouse plasma at 30 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695667 | Tmax in human MDA-MB-231 cells xenografted SCID mouse tumor at 30 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695645 | Cmax in human MDA-MB-231 cells xenografted SCID mouse plasma at 10 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1239109 | Cytotoxicity against human sensitive MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by Alamar Blue assay | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
| Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. |
| AID695637 | Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed inhibition of tumor growth at 30 mg/kg, po administered daily for 5 days/week for 2 weeks | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695461 | Induction of degradation of cIAP1 in human MDA-MB-231 cells at 10 nM by Western blot analysis | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695467 | Growth inhibition of human MDA-MB-231 cells after 4 days by WST8 assay | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695636 | Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed inhibition of tumor growth at 10 mg/kg, po administered daily for 5 days/week for 2 weeks | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID695665 | AUC (0 to t) in human MDA-MB-231 cells xenografted SCID mouse tumor at 30 mg/kg, po administered as single dose | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1346238 | Human baculoviral IAP repeat containing 3 (Inhibitors of apoptosis (IAP) protein family) | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1346249 | Human baculoviral IAP repeat containing 2 (Inhibitors of apoptosis (IAP) protein family) | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| AID1346157 | Human X-linked inhibitor of apoptosis (Inhibitors of apoptosis (IAP) protein family) | 2011 | Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |